Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
JJ Feld,
IM Jacobson,
Christophe HEZODE,
T Asselah,
PJ Ruane,
N Gruener,
A Abergel,
A Mangia,
CL Lai,
HL Chan,
F Mazzotta,
C Moreno,
E Yoshida,
SD Shafran,
WJ Towner,
TT Tran,
J McNally,
A Osinusi,
E Svarovskaia,
Y Zhu,
DM Brainard,
JG McHutchison,
K Agarwal,
S Zeuzem,
N Engl J Med. 31/12/2015;373(27) : 2599-2607 10.1056/NEJMoa1512610. 16/11/2015
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.
F About,
T Oudot-Mellakh,
J Niay,
P Rabiega,
V Pedergnana,
D Duffy,
P Sultanik,
C Cagnot,
F Carrat,
P Marcellin,
F Zoulim,
D Larrey,
Christophe HEZODE,
H Fontaine,
JP Bronowicki,
S Pol,
ML Albert,
I Theodorou,
A Cobat,
L Abel,
PLoS One. 15/12/2015;10(12) : e0145105 10.1371/journal.pone.0145105.
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients.
J Boursier,
A Ducancelle,
J Vergniol,
P Veillon,
V Moal,
C Dufour,
JP Bronowicki,
D Larrey,
Christophe HEZODE,
F Zoulim,
H Fontaine,
V Canva,
T Poynard,
S Allam,
V De Ledinghen,
J Viral Hepat. 01/12/2015;22(12) : 1002-1010 10.1111/jvh.12433. 27/07/2015
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
Jean-Michel PAWLOTSKY,
R Flisiak,
SK Sarin,
J Rasenack,
T Piratvisuth,
WL Chuang,
CY Peng,
GR Foster,
S Shah,
H Wedemeyer,
Christophe HEZODE,
W Zhang,
KA Wong,
B Li,
C Avila,
NV Naoumov,
Hepatology. 01/10/2015;62(4) : 1013-1023 10.1002/hep.27960. 10/08/2015
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
E Lawitz,
M Makara,
US Akarca,
PJ Thuluvath,
LL Preotescu,
P Varunok,
RM Morillas,
C Hall,
N Mobashery,
R Redman,
T Pilot-Matias,
RA Vilchez,
Christophe HEZODE,
Gastroenterology 01/10/2015;149(4) : 971-980.e1 10.1053/j.gastro.2015.07.001. 11/07/2015
Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
F Bailly,
V Virlogeux,
C Dufour,
P Pradat,
Christophe HEZODE,
D Larrey,
L Alric,
D Samuel,
M Bourliere,
S Metivier,
JP Zarski,
H Fontaine,
V Loustaud-Ratti,
L Serfaty,
JP Bronowicki,
F Carrat,
F Zoulim,
Clin Res Hepatol Gastroenterol. 01/09/2015;39(4) : 443-450 10.1016/j.clinre.2014.12.007 27/01/2015
Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4).
Christophe HEZODE,
L Alric,
A Brown,
T Hassanein,
M Rizzetto,
M Buti,
M Bourliere,
D Thabut,
E Molina,
V Rustgi,
D Samuel,
F McPhee,
Z Liu,
PD Yin,
E Hughes,
M Treitel,
COMMAND-4 study team
Anticir Ther 27/08/2015;21(3) : 195-205 10.3851/IMP2985.